Free fetal DNA (ffDNA) in maternal plasma has now become a valuable source for noninvasive prenatal diagnosis. Being able to accurately identify the size of ffDNA in maternal plasma is essential for a noninvasive prenatal diagnosis. Furthermore, it is important to investigate the molecular characteristics related to apoptosis which gives rise to ffDNA. We investigated the fragment size of ffDNA in each sample more precisely, using both Y-STR and SRY primers, in 20 maternal plasma samples from the 17th to 39th weeks of gestation. PCR was conducted with Y-STR and SRY primers which can be used to amplify 100-524 bp fragments. In samples from 10 pregnant women carrying male fetuses, the maximum fragment size detected by Y-STR and SRY primers ranged from 219 to 313 bp. As a result, the mean average maximum fragment size of free fetal DNA detected by Y-STR and SRY primers was 286±28 bp. The Y-STR alleles detected in each maternal plasma DNA sample were all in agreement with the results of their cord blood samples. We concluded that the fragment size of ffDNA comprises 2 nucleosomal complexes or less, but not exceeding 3.
INTRODUCTION
A significant proportion of cell-free DNA is bound to protein molecules as nucleosomes. Circulating DNA fragments are mainly sized in multiples of the nucleosomal DNA. 1, 2) The presence of fragmented DNA is reliable evidence of apoptosis, and this sign is widely used as a qualitative marker of cell death (apoptosis). 3, 4) The size characteristics of free fetal DNA (ffDNA) fragments from apoptosis have been analyzed. According to the work reported by Chan et al., 5) the median percentages of fetalderived DNA in maternal plasma with sizes >193 and > 313 bp were 20 and 0%, respectively, while Li Ying et al. 6) also reported that fragment sizes of less than -0.3 kb were enriched by fetal DNA.
Free fetal DNA concentration in maternal plasma increases as pregnancy advances, and placental apoptosis has been reported to increase with gestational age. [7] [8] [9] However, the precise maximum fragment size of ffDNA in maternal plasma throughout the pregnancy period has not yet been precisely reported.
We investigated the size distribution of ffDNA and related this to apoptosis-associated fragmentation using both Y-chromosomal short-tandem repeat (Y-STR) and SRY primers. Evaluating the fragment size of ffDNA is essential for choosing the target genes for noninvasive prenatal diagnosis and investigating the molecular characteristics related to the apoptosis of ffDNA.
We used a commercial AmpFlSTR ® Y-filer TM kit (Applied Biosystems, CA, USA), which can detect the size distributions of Y-STR fragments ranging from 100 to 325 bp, including 17 Y-STR loci. We also examined whether a > 313-bp fragment size was detectable in samples in which the Y-STR loci were determined by performing PCR using SRY primers (193, 313, 392 and 524 bp), as reported by Chan et al. 5) By combining these Y-STR and SRY primers, we were able to investigate the fragment size of ffDNA more precisely.
MATERIALS AND METHODS
Twenty pregnant women in their 17th to 39th weeks of gestation without pregnancy-associated complications were enrolled. Ethical approval for this project was obtained from the Saitama Medical University Ethics Committee, and all samples were obtained with informed consent.
Plasma preparation
Seven milliliters of peripheral blood was collected into tubes containing EDTA. The samples were first centrifuged at 3,000 g for 5 minutes at room temperature, and the plasma was then collected and subjected to further centrifugation at 10,000 g for 5 minutes. We also collected cord blood samples (2 mL) from each pregnant woman after delivery.
DNA extraction
Total plasma DNA was extracted with a QIA amp Mini Blood kit (Qiagen) according to the manufacturer's instructions. The plasma DNA isolated from 1 mL of maternal plasma was eluted in a final volume of 50 uL of AE buffer. Furthermore, we extracted DNA from 1 mL of cord blood (whole blood) to confirm our results after delivery.
PCR reaction 17 Y-STR loci multiplex amplification
Using maternal plasma samples, the 17 Y-STR loci were co-amplified using the AmpFlSTR Extracted cord blood DNA was diluted to 0.1 ng/uL in distilled water, and the PCR conditions were the same as those above, except for the number of PCR cycles, which was 30 after the initial denaturation step. Taq Gold TM (Applied Biosystems), and 10 uL of DNA. Following preheating at 95°C for 11 minutes, 40 cycles of amplification at 94°C for 1 minute, 55°C for 1 minute, 72°C for 1 minute, and a final extension of 60°C for 45 minutes were carried out in a GeneAmp PCR System 9700 (Applied Biosystems).
Detection of PCR products with capillary electrophoresis
Following the manufacturer's instructions, each sample mixture was prepared by adding 1.5 uL of PCR products to 24 uL of formamide, and 1 uL of internal-size standard ROX-500 (Applied Biosystems). The sample mixture was denatured at 95°C for 3 minutes, and then kept at 4°C in ice water. The results were analyzed using the GeneMapper TM ID Software Version 3.2 package (Applied Biosystems). A peak detection threshold of 50 RFUs (relative fluorescence units) was used for the SRY-specific peak, and 150 RFUs was the level for Y-STR allele designation.
RESULTS
Among plasma samples from 20 pregnant women, Y-STR loci were identified in 10. These ten mothers bore male infants, while the women carrying female fetuses showed no such peaks. Comparing the Y-STR genotyping results of maternal plasma samples carrying male fetuses with the results of their cord blood samples after delivery, the Y-STR alleles detected in each maternal plasma DNA sample were all concordant with the results of their cord blood samples (Table 1 ). All the ffDNAs of Y-STR observed in maternal plasma were detected in cord blood.
Based on the above 10 samples, the maximum fragment size detected by Y-STR genotyping of each sample ranged from 219 to 302 bp, with a mean of 275±26 bp (Table 1) . Combining Y-STR and SRY genotyping, the detected maximum fragment sizes of those 10 samples ranged from 219 to 313 bp, with a mean of 286±28 bp ( Figure 1 and Table 2 ).
DISCUSSION
The origin of circulating nucleic acids is presently unknown. Although previous studies have demonstrated that serum or plasma DNA levels are often increased in patients with various malignancies and in those with several benign diseases such as infections, sepsis, trauma, stroke, and autoimmune disease, [10] [11] [12] [13] the plasma DNA concentrations of those patients have been found to be closely correlated with the levels of circulating nucleosomes, which are products of apoptosis. 14) These findings suggest that increased rates of cell death events such as apoptosis or necrosis are considered the main sources of circulating fragmented DNA.
Free fetal DNA concentrations in maternal plasma increase as pregnancy advances and have also been found to correlate with the maternal human chorionic gonadotropin concentrations produced by syncytiotrophoblasts. 7, 8, 15) Furthermore, ffDNA concentrations are significantly elevated in fetal aneuploidy and preeclampsia. [16] [17] [18] [19] However, the precise clearance and release mechanisms of ffDNA also remain unknown.
Nucleosomal complexes consist of histones with ~146 bp of DNA on the outside. 20) Plasma DNA from cancer patients contains fragments of various lengths, ranging from small (180-bp or shorter mononucleosomes, and those twice, three times, and four times longer than the mononucleosomes) due to apoptosis as well as very large fragments (>10,000 bp) due to necrosis. In various pathological conditions including cancer, plasma DNA has been shown to circulate mainly in the form of mononucleosomes. [21] [22] [23] However, ffDNA cannot be visualized directly by electrophoresis because of the small amount of ffDNA in maternal plasma (0.39-11.4%) 8) as well as the presence of maternal DNA in the background.
Chan et al. 5) conducted PCR for ffDNA using six SRY primers varying in size from 107 to 524 bp, and demonstrating that product sizes of 313 bp or longer accounted for less than 1%, with most products being shorter than 193 bp. Jorgez et al. 24) conducted real-time PCR for a quantitative comparison of SRY genes between male fetuses and adult males, and revealed a significant difference at 100-300 bp, but not above that size, throughout the pregnancy period. Thus, it has been reported that 300-bp or shorter ffDNA fragments are present in abundance. Here, we used a Y-STR kit that can evaluate sizes in 4-bp increments between 100 and 325 bp to examine the presence of 200-300-bp-sized fragments in individual cases and the ffDNA status during apoptosis.
Although our results showed the mean maximum fragment size of ffDNA, 286 bp, to be caused by the apoptosis of 2 nucleosomal complexes, we found no fragment sizes indicating apoptosis of more than 3 nucleosomal complexes. We therefore concluded that the fragment size of ffDNA comprises 2 nucleosomal complexes or less throughout the pregnancy period.
This was a new finding, concerning the molecular characteristics of ffDNA, a potentially important clue to improving future prenatal diagnosis. SRY genotyping of 10 pregnant women (same as in Table 1 ). Combining Y-STR and SRY genotyping, the detected maximum fragment size of these 10 samples ranged from 219 to 313 bp, with a mean of 286±28 bp.
